PMA device
Dexcom CGM
Dexcom, Inc. · Sensor, Glucose, Invasive (MDS, Class III) · First FDA decision Aug 17, 2012, newest Aug 17, 2012Diabetes
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
PMA pathway
Device trials
282
Naming "Dexcom CGM"
MAUDE reports
39
Brand "Dexcom CGM", since 2015
PubMed studies
14
Mentioning "Dexcom CGM"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Dexcom CGM
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
- DEXCOM CGMPMA supplement
P050012-S045 · Decided Aug 17, 2012 · 178 days after receipt · Normal 180 Day Track
Device type: Sensor, glucose, invasive (MDS) · Laboratory Medicine & Pathology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Dexcom CGM", any status and sponsor, newest update first.
- Interventional Clinical Trial Evaluating COVER PATCH CAPTEUR PROTECT Support Solutions for Continuous Glucose Monitoring Sensors in Patients With DiabetesPivotal-lookingRecruiting
CAPTEUR PROTECTNot on our public-company list
NCT07018180 · 194 participants (planned) · Start Dec 5, 2025
Device: Use of COVER patchs for continuous glucose monitoring sensor · For: Diabetes
Sites: Bron, France; Corbeil-Essonnes, France; Grenoble, France · 10 sites in all
- Using Remote Monitoring to Address Health Disparities in Type 2 DiabetesPivotal-lookingEnrolling by invitation
Lawndale Christian Health CenterAcademic, hospital or other
NCT06517576 · 150 participants (planned) · Start Dec 1, 2024 · Primary completion Dec 31, 2026
Device: Blood glucose monitor with Digital Platform and Health Coaching; Continuous glucose monitor · For: Diabetes Mellitus, Type 2
Sites: Chicago, Illinois
- Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage ExerciseRecruiting
Stanford UniversityAcademic, hospital or other
NCT07226583 · 20 participants (planned) · Start Nov 6, 2026 · Primary completion May 2027
Device: netIOB & Exercise Toolkit (NEXT); Continuous Glucose Monitoring and 1 more · For: Type 1 Diabetes Mellitus; Exercise Physiology
Sites: Palo Alto, California
279 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Dexcom CGM", and for the whole product code for context.
This brand
39 reports: 16 malfunction, 21 injury, 0 death
Whole product code MDS
232,139 reports: 226,671 malfunction, 5,201 injury, 215 death
Newest reports for this brand
- Dexcom CGMOther
MW6004554 · Received Oct 26, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Defective Device; Output Problem
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
- DEXCOM CGM G6Injury
MW5187388 · Received Apr 28, 2026 · Event dated Apr 23, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Low Readings; Communication or Transmission Problem
Patient problem as coded: Hyperglycemia
- DEXCOM CGM G6Injury
MW5187389 · Received Apr 28, 2026 · Event dated Apr 23, 2026
Device type: Integrated Continuous Glucose Monitoring System, Factory Calibrated (QBJ)
Device problem as coded: Low Readings; Communication or Transmission Problem
Patient problem as coded: Hyperglycemia
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Dexcom CGM"[tiab]. The summary above synthesizes these.
- Continuous Glucose Monitoring Metrics Predict All-Cause Mortality in Diabetes: A Real-world Long-term Study.
Okuno T, Macwan SA, Norman GJ, et al. · Diabetes Care · 2025
- Inaccurate Glucose Sensor Values After Hydroxyurea Administration.
Tellez SE, Hornung LN, Courter JD, et al. · Diabetes Technol Ther · 2021
- Long-Term Improvements in Glycemic Control with Dexcom CGM Use in Adults with Noninsulin-Treated Type 2 Diabetes.
Layne JE, Jepson LH, Carite AM, et al. · Diabetes Technol Ther · 2024Observational Study, Research Support, Non-U.S. Gov't
- An Analysis of 2019 FDA Adverse Events for Two Insulin Pumps and Two Continuous Glucose Monitors.
Krouwer JS · J Diabetes Sci Technol · 2022
- Accuracy of Two Continuous Glucose Monitors Differs after Hydroxyurea in Pediatric Patients Undergoing Total Pancreatectomy with Islet Autotransplantation.
Ladd JM, Gandhi K, Friesner-Gephart K, et al. · Diabetes Technol Ther · 2025Research Support, Non-U.S. Gov't
- Design and Clinical Evaluation of a Novel Low-Glucose Prediction Algorithm with Mini-Dose Stable Glucagon Delivery in Post-Bariatric Hypoglycemia.
Laguna Sanz AJ, Mulla CM, Fowler KM, et al. · Diabetes Technol Ther · 2018Research Support, N.I.H., Extramural
- Assessing Patterns of Continuous Glucose Monitoring Use and Metrics of Glycemic Control in Type 1 Diabetes and Type 2 Diabetes Patients in the Veterans Health Care System: Integrating Continuous Glucose Monitoring Device Data with Electronic Health Records Data.
Okuno T, Macwan SA, Miller D, et al. · Diabetes Technol Ther · 2024Observational Study, Research Support, U.S. Gov't, Non-P.H.S.
- Updated glucose management indicator (GMI) better aligns with HbA1c than current GMI: implications for clinical practice and reporting.
Bergenstal RM, Xu Y, Dunn TC, et al. · Diabetologia · 2026
- Toward Calibration-Free Continuous Glucose Monitoring Sensors: Bayesian Calibration Approach Applied to Next-Generation Dexcom Technology.
Acciaroli G, Vettoretti M, Facchinetti A, et al. · Diabetes Technol Ther · 2018
- Impact of race and delayed adoption of diabetes technology on glycemia and partial remission in type 1 diabetes.
Chader-Gata Garcia A, Kaur K, Talib R, et al. · J Pediatr Endocrinol Metab · 2025
- Temporal Glycemic Patterns in Type 1 and Type 2 Diabetes: Insights From Extended Continuous Glucose Monitoring.
Okuno T, Sort L, Zhang B, et al. · J Diabetes Sci Technol · 2026
- Model of glucose sensor error components: identification and assessment for new Dexcom G4 generation devices.
Facchinetti A, Del Favero S, Sparacino G, et al. · Med Biol Eng Comput · 2015
Other devices of this type
Also filed under product code MDS.
- Dexcom G4 Platinum Continuous Glucose Monitoring System and Dexcom 5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2018
- G5 Mobile Continuous Glucose Monitoring SystemDexcom, Inc. · PMA 2024
- FreeStyle Libre Pro Flash Glucose Monitoring SystemAbbott Diabetes Care, Inc. · PMA 2020
- Freestyle Navigator Continuous Glucose Monitoring SystemAbbott Laboratories · PMA 2011
- Paradigm Real-Time Insulin PumpMedtronic Minimed · PMA 2015
- Medtronic Minimed Continuous Glucose Monitoring SystemMedtronic Minimed · PMA 2011
- Guardian Connect SystemMedtronic Minimed · PMA 2025
- Dexcom Seven SystemDexcom, Inc. · PMA 2009
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.